Tempus, a health technology company focused on personalized oncology care, will collect and analyze clinical and molecular data to support Moores Cancer Center’s research on immune checkpoint inhibitors across cancer types.
The company will also help the center incorporate genomic data into its clinical and research practices.
“Collecting and analyzing patients’ molecular, treatment and outcome data will be transformative for patients, researchers and the healthcare ecosystem,” said Eric Lefkofsky, co-founder and CEO of Tempus.
More articles on health IT:
Bloomberg: Kaspersky Lab tied to Russian government
3 Florida ACOs tap eClinicalWorks for population health management
Norwegian academic, healthcare institutions partner for blockchain research network
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
